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Mutations in the N-terminal Actin-Binding
Domain of Filamin C Cause a Distal Myopathy
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Paul Kennedy,5 Alina Steinbach,6 Wiebke Scho¨ffler,6 Peter F.M. van der Ven,6 Dieter O. Fu¨rst,6
Jaeguen Song,7 Kristina Djinovic-Carugo,7,13 Sini Penttila¨,8 Olayinka Raheem,8 Katrina Reardon,3
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David R. Williams,11 John E. Landers,12 Robert H. Brown, Jr.,12 Bjarne Udd,4,8,14 and Nigel G. Laing1,*
Linkage analysis of the dominant distal myopathy we previously identified in a large Australian family demonstrated one significant
linkage region located on chromosome 7 and encompassing 18.6 Mbp and 151 genes. The strongest candidate gene was FLNC because
filamin C, the encoded protein, is muscle-specific and associated with myofibrillar myopathy. Sequencing of FLNC cDNA identified
a c.752T>C (p.Met251Thr) mutation in the N-terminal actin-binding domain (ABD); this mutation segregated with the disease and
was absent in 200 controls. We identified an Italian family with the same phenotype and found a c.577G>A (p.Ala193Thr) filamin C
ABD mutation that segregated with the disease. Filamin C ABD mutations have not been described, although filamin A and filamin B
ABD mutations cause multiple musculoskeletal disorders. The distal myopathy phenotype and muscle pathology in the two families
differ from myofibrillar myopathies caused by filamin C rod and dimerization domain mutations because of the distinct involvement
of handmuscles and lack of pathological protein aggregation. Thus, like the position of FLNA and Bmutations, the position of the FLNC
mutation determines disease phenotype. The two filamin CABDmutations increase actin-binding affinity in amanner similar to filamin
A and filamin B ABD mutations. Cell-culture expression of the c.752T>C (p.Met251)Thr mutant filamin C ABD demonstrated reduced
nuclear localization as did mutant filamin A and filamin B ABDs. Expression of both filamin C ABD mutants as full-length proteins
induced increased aggregation of filamin. We conclude filamin C ABD mutations cause a recognizable distal myopathy, most likely
through increased actin affinity, similar to the pathological mechanism of filamin A and filamin B ABD mutations.Introduction
The distal myopathies are a group of genetic muscle-
wasting disorders characterized by muscle weakness
predominantly originating in distal muscle groups of the
upper or lower limbs.1,2 Currently, the many types of distal
myopathy are differentiated by the phenotypic variations
within the disease spectrum. These include age at onset,
affected muscle groups, severity, presence of cardiomyop-
athy, and mode of inheritance. The distal myopathies
show either dominant or recessive inheritance, and the
genetic basis for several of the distal myopathies has
been determined. The known proteins affected in distal
myopathies encompass a range of different types but
include a significant number of sarcomeric proteins1
(Table 1).3–12 In addition, patients with diseases described
by other terms, such as myofibrillar myopathy, also often
have a distal myopathy phenotype.2 The genetic basis of
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The Ameathy (WDM [MIM 604454]), one of the first distal myopa-
thies described,13 remains unknown.2
In 2005 we described in a large family from Victoria,
Australia,14 a distal myopathy sometimes termed Distal
ABD-filaminopathy or William’s myopathy15. The distal
myopathy in the family did not link to any of the then
known distal myopathy loci, which reinforced the novel
clinical phenotype.14 Here we have reanalyzed the clinical
phenotype, reclassified the members in the family, and
performed a whole-genome linkage analysis. Significant
linkage for the disease in the family (multipoint LOD score
3.3) was obtained on chromosome 7. We subsequently
identified a second family from Italy with the same pheno-
type and showed that the disease in this second family was
compatible with linkage to the same region of chromo-
some 7. We found two different missense mutations in
the N-terminal ABD of FLNC (MIM 102565), and both
mutations segregate with the disease in the two families.
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Table 1. Distal Myopathies with Known Genes
Disease Gene Protein Type
Dominant
Tibial muscular dystrophy
(TMD, Udd myopathy
[MIM 600334])
Titin (TTN [MIM
188840])3
sarcomeric
Laing myopathy (MPD1
[MIM 160500])
slow skeletal/b-cardiac
myosin (MYH7 [MIM
160760])4
sarcomeric
Desminopathy (MIM
601419)
desmin (DES [MIM
608810])1
sarcomeric
Markesbery-Griggs distal
myopathy
ZASP (LDB3 [MIM
605906])5
sarcomeric
Distal myopathy with
vocal cord and pharyngeal
weakness (MPD2 [MIM
606070])
matrin 3 (MATR3
[MIM 164015])6
nuclear matrix
Early-onset distal
myopathy
kelch-like homolog 9
(KLHL9 [MIM 611201])58
ubiquitylation
Recessive
Miyoshi distal myopathy
(MMD1 [MIM 254130])
dysferlin (DYSF [MIM
603009])7,8
sarcolemmal
Nonaka distal myopathy
(NM [MIM 605820])/
hereditary inclusion body
myopathy (IBM2 [MIM
600737])
UDP-N-
acetylglucosamine-2-
epimerase/N-
acetylmannosamine
kinase (GNE [MIM
603824])9,10
enzyme
Nebulin early-onset distal
myopathy
nebulin (NEB [MIM
161650])11
sarcomeric
Miyoshi myopathy type 3
(MMD3 [MIM 613319])
anoctamin 5 (ANO5
[MIM 608662])12
transmembranerevealed increased affinity for actin. Cell-culture transfec-
tion studies with mutant filamin C proteins demonstrated
altered nuclear localization and aggregate formation.Material and Methods
Approvals
All sample collection and experimentation was performed with
informed consent from the patients according to approvals given
by the University of Western Australia Bioethics Committee or
with informed consent from the patients, according to the Decla-
ration of Helsinki.
Skeletal Muscle Pathology
Victorian Family
Collected biopsy tissue was immediately frozen in liquid nitrogen-
chilled isopentane and was routinely processed for histology and
histochemistry. Immunocytochemical analysis was performed
with the following antibodies: dystrophin (Dys1, Dys2, Dys3),
dysferlin, myotilin, merosin, titin, sarcoglycans (a, b, g, d, and
3), aB-crystallin (Leica Microsystems, Newcastle Upon Tyne, UK),
laminin b, laminin g, and collagen VI (Millipore, MA, USA),
with a horseradish peroxidase detection system. Filamin location
was determined with the RR90 antibody,16 followed by incubation
with a rabbit anti-mouse IgA secondary and a goat anti-rabbit730 The American Journal of Human Genetics 88, 729–740, June 10,Alexa Fluor 488 tertiary antibody. Nuclei were labeled with
Hoechst.
Italian Family
Muscle biopsy samples were originally analyzed with routine
histology and histochemical stainings. After identification of the
mutated gene, samples were processed for immunohistochemical
analysis with a panel of antibodies against myotilin (Leica Micro-
systems, Newcastle Upon Tyne, UK), desmin (Biogenex Laborato-
ries, CA, USA), aB-crystallin (Leica Microsystems, Newcastle Upon
Tyne, UK), filamin C (Sigma-Alderich, MO, USA), actin (Invitrogen
Corporation, CA, USA), and a-actinin (Sigma-Alderich, MO, USA)
to assess myofibrillar protein aggregation. The immunohisto-
chemical stainings were made with the BenchMark Immunos-
tainer (Ventana Medical Systems, Arizona, USA) with a peroxi-
dase-based detection kit (Universal DAB Detection Kit, Ventana
Medical Systems, Arizona, USA).Linkage Analysis
Victorian Family
A genome-wide SNP screen was performed on DNA from the
Victorian family with the Xba 142.2 10K array system (Affyme-
trix). Allegro17 was used to calculate linkage. Pelican 1.2.018
created pedigree files, and Alohomora v0.2619 generated input files
for Allegro. Pedcheck20 was utilized to check for Mendelian errors.
Haplotypes were viewed with the program Haplopainter
v0.24Beta.21 LOD scores were calculated with the disease allele
frequency set to 1/10,000 and assuming complete penetrance.
Italian Family
Linkage analysis to the FLNC region on chromosome 7 was per-
formed with six microsatellite markers (D7S2471, D7S686,
D7S2501, D7S2519, D7S2531, D7S1804) distributed over a
6.4 Mb region around FLNC. Sets of microsatellite markers for
the genes GNE (MIM 603824), MYH7 (MIM 160760), MYOT
(MIM 604103), TTN (MIM 188840), TPM2 (MIM 190990), VCP
(MIM 601023), WDM (MIM 604454), and ZASP (MIM 605906)
were also used for genotyping of the samples.FLNC Sequencing
The entire FLNC (NM_001127487.1) transcript was sequenced
upon amplification of six overlapping fragments. Template
cDNAwas synthesized frommRNA extracted from skeletal muscle
biopsies of two affected family members from the Victorian family
and one control sample. For the Italian family, the N-terminal
exons 2–10 of FLNC were sequenced from genomic DNA. The
primers used for amplifying and sequencing the fragments were
designed with the Primer3 software (Table S1, available online).
PCR products were sequenced on an ABI3730, automatic DNA
sequencer system (Applied Biosystems, Foster City, CA) with the
Big Dye Terminator kit and analyzed with Sequencher 4.8 software
(Gene Codes Corporation, Ann Arbor, MI).Mutation Screening in Control Individuals
The c.752T>C (p.Met251Thr) mutation identified in the Victorian
family creates a MaeIII restriction site not present in the wild-type
sequence. MaeIII (New England Biolabs) digestion (as per the
manufacturer’s guidelines) was therefore used to screen DNA
samples from unrelated control individuals. We performed
screening of controls for the c.577G>A (p.Ala193Thr) mutation
identified in the Italian family by sequencing exon 2 of FLNC
(forward: 50-AAGAACTTGGCATCTGAGTGG-30; reverse: 50-GGTG
TGCATTCTGACAACCA-30).2011
Cloning of Truncated and Full-Length Filamin C Constructs
Three different regions of FLNCwere amplified fromwild-type and
Victorian family patient skeletal muscle cDNA encompassing: (1)
the CH1 and CH2 domains, (2) both CH domains and the region
between CH2 and immunoglobulin-like (Ig-like) repeat 1, and (3)
both CH1 domains and Ig-like repeat 1 (Figure S1 and Table S2).
These fragments were cloned into the pET44a or pGEX6P1 vectors
to enable prokaryotic expression or the pEGFP-N1 expression
vector (Clontech) for eukaryotic expression. The three different
p.Met251Thr mutant filamin C fusion proteins localized similarly
to one another yet differently to the three wild-type constructs.
Therefore, in subsequent experiments, the corresponding longer
versions of the ABDs of filamin A and filamin B were also amplified
from skeletal muscle cDNA and cloned into pEGFP-N1. The FLNA
[MIM 300017] and FLNB [MIM 603381] mutations and the FLNC
p.Ala193Thr mutation were introduced by amplification of the
template with primers containing the mutant sequence.
A full-length FLNC cDNA clone in pEGFP-N3 was obtained in
two steps. A fragment encoding domains 15–24 was amplified
by PCR from a human skeletal muscle cDNA library (Clontech)
and cloned into vector pEGFP-N3 (Table S3). Subsequently, a frag-
ment encoding ABD-d15 was amplified with a FLNC cDNA as
a template (HP07616-ARi57A02, deposited by Seishi Kato,
Research Institute of National Rehabilitation Center for Persons
with Disabilities and provided by the RIKEN BioResource Center)
and cloned in the partial FLNC clone with a unique BclI restriction
site within the cDNA encoding d15 to obtain a full-length
construct. From the above-mentioned mutant FLNC ABD and Ig-
like repeat 1 constructs, an EcoRI/AccI fragment encoding the
ABD and part of repeat 1 was purified and used in place of the
equivalent wild-type fragment in the full-length FLNC clone in
pEGFP-N3. This substitution method was used to produce both
mutant FLNC variants.
Expression and Purification of Recombinant Proteins
Protein expression was performed as described previously.22 Trun-
cated cDNA fragments were cloned either into the prokaryotic
expression vector pET44a, resulting in fusion proteins carrying
a C-terminal His6-NusA tag, or into pGEX-6P1 (Amersham),
enabling expression of glutathione S-transferase (GST) fusion
proteins. His6-tagged proteins were expressed in E. coli BL21-Co-
donPlus(DE3)-RIL (Novagen) and purified with the QiaExpress
kit as described by the manufacturer (QIAGEN). The Nus-His6
tag (pET44a) was removed by tobacco etch virus protease (10 mg/
ml) cleavage overnight at 16C. GST-tagged proteins were ex-
pressed in E. coli and purified on Glutathione-Uniflow Resin
columns (Clontech). GSTwas cleaved from the proteins with PreS-
cission Protease (Amersham) according to the recommendations
of the manufacturer. Protein concentrations were determined by
densitometric calculation (Odyssey Infrared Imaging System, LI-
COR Biosciences GmbH, Bad Homburg).
Biophysical Characterization
Circular dichroism spectroscopy was performed after dialysis of
purified proteins against 150mM sodium phosphate andmeasure-
ment of the concentration at 280 nm with the extinction coeffi-
cient 55,460 M1cm1. Equal protein quantities of wild-type
ABD or both mutant ABDs in 300 ml buffer were added to
a 1 mm quartz cuvette, and CD spectra were recorded from
190 nm to 260 nmwith a Pistar-180 spectrometer (Applied Photo-
physics). For differential scanning fluorimetry (Thermofluor)
stability assays, 5 ml SYPRO Orange dye (30x, Invitrogen) was
added to 10 ml protein sample. Assays were carried out in an IQ5
real-time PCR detection system (Bio-Rad). Temperatures variedThe Amefrom 20C–95C with a fluorescence excitation at 470 nm and
detection at 555 nm.
Limited Proteolysis
Proteolytic susceptibility was investigated with the endopeptidase
thermolysin (Sigma). The protein was diluted to 10 mM (50 mM
NaH2PO4, 300 mM NaCl, and 250 mM imidazole [pH 8.0]);
10 mg/ml thermolysin was added, and the mixture was incubated
at 37C. At each incubation interval, the reaction was stopped by
adding 0.2 vol. 53 SDS sample buffer. The samples were run on
a 12% polyacrylamide gel, and band intensities were measured
by densitometry.
Cosedimentation Actin-Binding Assay
Muscle actin was purified from acetone powder prepared from
chicken breast muscle as described.23 Cosedimentation assays
were performed essentially as described previously.24 Equal
volumes of supernatant and pellet were analyzed by polyacryl-
amide gel electrophoresis (12% w/v). Gels were stained with Coo-
massie Brilliant Blue, and protein bands were quantified by densi-
tometry with the Odyssey Imaging System (LI-COR). Ten samples
were assayed for each ABD, and the results were combined for
hyperbole regression analysis. Calculation of Kd values and defini-
tionof thecoefficientof correlationwereperformedwithGraphPad
Prism (GraphPad Software).
Cell Culture
C2C12myoblasts, COS7, HEK293, and HeLa cells were resurrected
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 4 mM L-glutamine (Sigma-Aldrich) and 10% fetal calf serum
(GIBCOBRL). Cells were seeded onto coverglass coated withMatri-
gel (BD Biosciences) and transfected with the pEGFP-N1þFLN
vectors with Lipofectamine 2000 (Invitrogen). The following
day, the C2C12 cultures were placed into DMEM containing 5%
horse serum to promote myotube formation. Cells were fixed
24–48 hr posttransfection in 2% paraformaldehyde, except the
C2C12 myotubes, which were fixed between day 5 and 6 of myo-
tube differentiation.
After fixation, cells were washed in PBS and mounted with Hy-
dromount (National Diagnostics). For transfection of the full-
length wild-type and mutant filamin C constructs, PtK2, or
C2C12 cells were grown, transfected, and stained essentially as
described.16,24 The formation of aggregates after transfection of
C2C12 cells with wild-type, p.Met251Thr, and p.Ala193Thr fila-
min C was characterized by protein distribution and estimation
of aggregate number and size in individual cells (n ¼ 110). Cells
were visualized and photographed with an Olympus IX71 or
a Zeiss Axio Imager M1 microscope equipped for fluorescence
and a Biorad MRC 1000/1024 confocal microscope.Results
Refinement of the Victorian Family Phenotype
Further analysis of the affected members of the Australian
family refined the clinical phenotype to identify nine
affected and three unaffected individuals available for
study. The disease most often started in the third decade
of life in the hands and was characterized by thenar muscle
weakness leading to reduced grip strength. This was fol-
lowed by calf muscle weakness beginning around the
fourth decade of life and leading to difficulties in running
and jumping. Progression to proximal muscles was evident
in the fifth decadeof life and usually required a stick forrican Journal of Human Genetics 88, 729–740, June 10, 2011 731
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Figure 1. Muscle Wasting in Patients of
the Victorian and Italian Distal Myopathy
Families
(A) A computed tomography (CT) scan of
the lower leg in a 39-year-old female
patient from the Victorian family. Severe
fatty degeneration of both soleus muscles
and right peroneal muscles is evident;
there is slightly less involvement of medial
and lateral gastrocnemius muscles and
radiologically normal anterior compart-
ment and tibialis posterior muscles.
(B) CT imaging of the lower legs in
the Italian male patient. Severe fatty
degeneration of soleus and gastrocnemii
muscles are evident with less severe changes in peroneal muscles and sparing of anterior compartment and tibialis posterior
muscles.
(C) Marked atrophy of thenar muscles in patient III:3 from the Italian family (marked by arrow).walking in the sixth decade of life. The distribution of the
most affected calf muscles was easily shown by muscle
imaging as a striking selective fatty degeneration of poste-
rior compartment muscles in the lower leg (Figure 1). Early
changes in thigh muscles are fatty degeneration of semi-
membranosus and semitendinosus muscles and later
involvement of all hamstring muscles, the adductor mag-
nus, and, even later, vastii muscles of the quadriceps. Elec-
tron microscopy studies on one muscle biopsy did not
demonstrate any pathological features. There are no mani-
festations of respiratory or cardiac insufficiency even at an
advanced age of more than 75 years.
Muscle Pathology in the Victorian Family
Muscle biopsies were reviewed on four family members
with a spectrum of findings determined (Figure S2).
Necrosis, vacuoles, inclusions, regeneration, and inflam-
mation were not observed. The array of antibodies showed
no major reactivity outside that of a normal muscle, and
electron microscopy did not show myofibrillar pathology.
Patient 1 biopsies, taken from the left bicep at 54 years of
age, showed nonspecific changes and a very occasional
rounded atrophic muscle fiber.
Patient 2 biopsies collected at 44 years of age, were of
end-stage myopathic muscle with extensive fatty atrophy.
Residual fibers showed fiber size variation and atrophic
rounded fibers of both fiber types. Internal nuclei and fiber
splitting were not seen. There were no ragged red fibers or
cytochrome oxidase-depleted fibers, and there was no
evidence of any change in distribution of the oxidative
enzymes. The array of antibodies showed scant internaliza-
tion of dysferlin, aB crystallin in a few fibers, and fine gran-
ular myotilin deposits within the cell.
Patient 3 biopsies taken from the left vastus medialis
at 76 years of age showed features of a myopathy and
minor variation in myofiber size in both fiber types. There
was no increase in the number of internal nuclei, and
there were no split fibers. Scattered fibers showed an
irregular flocculent pale eosinophilic material within the
cytoplasm, but no vacuoles were seen that appeared to
correlate with areas lacking oxidative enzyme activity.732 The American Journal of Human Genetics 88, 729–740, June 10,Gomori Masson stains showed scant fibers with subsarco-
lemmal accumulation of basophilic material. Many fibers
showed a moth-eaten appearance on oxidative enzyme
stains.
Patient 4 biopsies taken from the left soleus at 47 years of
age showed a myopathic pattern of patchy variation in
fiber size and scattered tiny atrophic fibers that appeared
eosinophilic and were of both fiber types. The muscle ap-
peared to be type 1 dominant. There was a focal increase
in interstitial fibrosis, a focal minor elevation in internal
nuclei, and scant degenerating fibers. There was an exten-
sive moth-eaten appearance to fibers, a loss of oxidative
enzyme stains, and patchy irregular cytochrome oxidase
negativity. The array of antibodies showed minor patchy
loss of surface dysferlin but no other evident change in
the distribution of the fibers.
Identification of an Italian Family
The refinement of the clinical and muscle imaging pheno-
type in the Australian family facilitated the identification
of the same phenotype in a family from Italy from among
the distal myopathy families who had been referred to us
for molecular genetic evaluation. There are four known
affected members in the pedigree (Figure 2).
All three available patients experienced reduced finger
skills and running performance at approximately 30 years
of age. Slow progression to the proximal lower limbmuscle
occurred over the following 20 years, and there was
evident atrophy of the hand muscles (Figure 1), an
inability to squat, and use of a stick for walking by age
60. Creatine kinase levels were only slightly elevated and
ranged from 1.53 to 2.53 the normal upper limit in all
three patients examined. There were no respiratory
features evident in the examined family members, but
two out of the four patients had cardiomyopathy.
Muscle Pathology in the Italian Family
Muscle pathology in the Italian family was derived from
a less affected deltoid muscle biopsy showing nonspecific
changes such as a variation of fiber size with scattered atro-
phic fibers and an increase of internal nuclei but no fiber2011
Figure 2. Pedigree of the Italian Family
Pedigree of the Italian family with distal myopathy identified in this study. The segregation of haplotypes around FLNC chromosome 7
are represented by colored bars. Samples with DNA available for study are marked with an asterisk (*). Inferred haplotypes are enclosed
with brackets. A recombination betweenmicrosatellites D7S2519 andD7S2531was observed in individual III:1. FLNC is located between
markers D7S2501 and D7S2519.necrosis or rimmed vacuolar changes. The results of immu-
nohistochemical analysis with a panel of antibodies re-
vealed that the characteristic protein aggregations, as
observed in myofibrillar myopathology, were not present
in the sample from the Italian family (individual III:1)
(Figure S3).
Linkage Studies
In view of the refined clinical phenotype in the Victorian
family, especially in relation to the age at onset, allmembers
of the youngest generation of the Victorian family were
classified as unknown for the purposes of linkage analysis.
In addition, all family members who could not be re-exam-
ined were also classified as unknown. Thus, nine affected
and three unaffected family members were included in
the linkage analysis. Genome-wide SNP analysis with the
Xba 142.2 10K array system (Affymetrix) identified a single
significant multipoint LOD score of 3.3 on chromosome 7
(Figure S4). The linkage region encompassed 18.6 Mbp
between SNPs rs754920 (128,468,162 bp) and rs1406288
(147,110,180 bp).
The smaller Italian family was shown to be compatible
with linkage to the same region by analysis of the microsa-
tellites D7S2471, D7S686, D7S2501, D7S2519, D7S2531,
and D7S1804 distributed over a 7.2 Mb region. The linked
region encompassed less than 6 Mb of this area between
markers D2S2471 and D67S2531 (Figure 2).The AmeFLNC Mutation Screening
The 18.6 Mbp linkage region in the Victorian family con-
tained an estimated 151 genes. The gene for filamin C
(FLNC) was considered the most likely candidate gene
within the linkage region on the basis of its role in skeletal
muscle structure and function and the fact that mutations
in this gene had previously been associated with myofi-
brillar myopathy.25,26 The entire FLNC cDNA from two
affected family members of the Victorian family was
sequenced. A thymine to cytosine transition mutation re-
sulting in a c.752T>C (ATG > ACG; p.Met251Thr) muta-
tion was detected in exon 4 (Figure 3). The mutation segre-
gatedwith the disease in the family giving a two-point LOD
score of 3.31. The mutation was not present in 200 unre-
lated control individuals (400 chromosomes) screened.
In the Italian family, sequencing the N-terminal exons
2–10 of FLNC from genomic DNA identified a c.577G>A
(GCC > ACC; p.Ala193Thr) mutation in exon 2 (Figure 3).
This mutation segregated with the disease in the family
and was not seen in 102 control individuals (204 chromo-
somes).
Biophysical Characterization and Actin-Binding
Assay
In order to investigate potential alterations of biophysical
and biochemical properties caused by the described
mutations, we first analyzed the secondary structure byrican Journal of Human Genetics 88, 729–740, June 10, 2011 733
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Figure 3. Mutations in the Filamin C Protein
(A) The filamin C protein with the position of the two mutations identified in this report marked on the ABD. The mutations in Ig-like
repeats 7 and 24 responsible for myofibrillar myopathy [MIM 609524] are also indicated.
(B) Chromatogram showing the c.752T>C heterozygous missense mutation resulting in a p.Met251Thr amino acid change identified
in the Victorian family.
(C) Chromatogram showing the c.577G>A missense mutation resulting in a p.Ala193Thr amino acid change identified in the Italian
family.
(D) Multiple sequence alignment of homologous ABDs with known mutations highlighted in red, mutations investigated in transient
transfection experiments in cell culture in this report highlighted in green, and the position of the mutations identified in this study
highlighted in gray.performing circular dichroism spectroscopy of bacterially
expressed ABDs. In accordance with the established crystal
structures of filamin ABDs, both the wild-type and the
mutant proteins exhibited a high proportion of a helices,
as evidenced by two minima in the spectrum at 208 and
222 nm and a maximum at 200 nm. The spectrum of the
p.Ala193Thr mutant was essentially identical to the wild-
type protein, whereas the p.Met251Thr mutant showed
slightly decreased ellipticity at the 200 nm and 222 nm
peaks (Figure 4A).
To test whether these alterations would translate into
changes of protein stability, we performed a fluorescence-
based thermal shift assay (Thermofluor) of p.Met251Thr
and p.Ala193Thr in comparison to the wild-type filamin
C ABD. This revealed a melting temperature of 59.3C for
the wild-type ABD, whereas the p.Met251Thr and
p.Ala193Thr mutant ABDs showed decreased average734 The American Journal of Human Genetics 88, 729–740, June 10,melting temperatures of 51C and 52.3C, respectively. A
limited thermolysin protease digestion was performed as
a second test of protein stability. At 37C this assay did
not reveal any significant differences between the wild-
type, the p.Met251Thr, and the p.Ala193Thrmutant ABDs.
To further analyze the binding capacities of wild-type
and mutant ABDs to F-actin in a quantitative manner, we
performed actin filament cosedimentation assays. All
ABDs clearly bound to and cosedimented with skeletal
muscle F-actin in a dose-dependent manner (Figure 4B).
Whereas the wild-type ABD had a calculated Kd value of
8.2 mM, the Kd of the p.Ala193Thr mutant was moderately
elevated (5.7 mM), and the p.Met251Thr mutant demon-
strated a highly increased actin-binding activity with
a Kd of 3.7 mM (Figure 4C). As a comparison, the Kd of
the ABDs of filamin A and filamin B was reported to be
17mM and 7.0 mM, respectively.27,282011
Figure 4. Protein Foldedness and Actin-Binding Assays
(A) Circular dichroism spectroscopy in the far UV range was per-
formed with purified, bacterially expressed wild-type and mutant
filamin ABD constructs. The mean residue ellipticity (MRE) shows
two minima in the spectrum at 208 and 222 nm and a maximum
at 200 nm, typical for the presence of a high proportion of
a helices. Note that the spectra of the wild-type and p.Ala193Thr
mutant are almost identical, whereas the MRE of the p.Met251Thr
mutant shows a slightly decreased ellipticity compared to the
ellipticity of the p.Ala193Thr and wild-type constructs.
(B and C) Actin-binding assays of filamin C wild-type and mutant
ABDs. (B) The results of high-speed F-actin cosedimentation assays.
The numbers on top of each lane indicate the amount of recombi-
nant ABD added to 5 mM actin. Given are the supernatant (S) and
pellet (P) fractions. The following abbreviations are used: C1,
controlwithoutABD;C2, controlwithout actin. (C) Binding curves
with F-actin. The mutant proteins exhibited increased actin-
binding activity, represented by a change in dissociation constant
(Kd) to 3.7 mM for p.Met251Thr and 5.7 mM for p.Ala193Thr
when compared to the wild-type filamin C (Kd ¼ 8.2 mM).Analysis of Wild-Type and Mutant Filamins A, B,
and C in Cell Culture
Three different length amino terminal constructs of wild-
type, p.Met251Thr, or p.Ala193Thr filamin C encompass-
ing the ABD, the ABD and the adjacent linker, or theThe AmeABD in addition to the first Ig-like repeat were cloned
into a pEGFP-N1 vector and transfected into C2C12,
COS-7 (Figure S5), HEK293, and HeLa cells. By fluorescence
and confocal microscopy, several gross morphological
differences were observed in C2C12 cells expressing the
three mutant fusion proteins in comparison to those ex-
pressing any of the three wild-type fusion proteins. These
included an increased presence of stress fibers, increased
length and intricacy of projections from the cell, and lower
intensity of fluorescent signal in the nucleus of the mutant
as compared to the nucleus of the wild-type (Figure S6).
Additionally, all three truncated filamin C (WT)-EGFP
fusion proteins localized to both the nuclei and sarcoplasm
of C2C12 cells, whereas the filamin C-(p.Met251Thr)-
EGFP fusion proteins showed significantly diminished
nuclear localization. This disparity in nuclear localization
between wild-type and p.Met251Thr filamin C ABD was
found in all transfected cell lines, including COS-7
(Figure S5), HEK293, and HeLa cells (not shown).
Transfection of COS-7 (Figure S5), HEK293, andHeLa cells
with wild-type and mutant filamin A (NM_001110556.1)
(c.760G>A, p.Glu254Lys) and filamin B (NM_001164317.1)
(c.679G>A, p.Glu227Lys and c.703T>C, p.Ser235Pro)
constructs, equivalent to the longest of the three filamin C
constructs (ABD and repeat 1), demonstrated a similar effect
of reduced nuclear localization of each the mutant fusion
proteins compared to nuclear localization in the wild-type
fusion proteins. In contrast, the fusion proteins containing
the Italian family mutation in FLNC (p.Ala193Thr) showed
a similar localization pattern to the wild-type in COS-7 cells
(Figure S5) and all further cell lines examined (C2C12,
HEK293, and HeLa cells).
To analyze the effect of the expression of both filamin C
mutations in PtK2 epithelial cells and C2C12 myoblasts,
we transiently transfected these cells with constructs en-
coding full-length wild-type or mutant filamin C. In PtK2
as well as C2C12 cells, expression of wild-type filamin C
resulted in an association of the EGFP fusion protein
with stress fibers (Figures 5A and 5D). The variants
p.Met251Thr and p.Ala193Thr also associated with stress
fibers (Figures 5B, 5C, 5E, and 5F).Otherwise, expression
of both mutants, but not the wild-type protein, resulted
in the development of protein aggregates in up to 100%
of the transfected cells (Figures 5B, 5C, 5E, and 5F).
Costaining with phalloidin revealed that these aggregates,
especially the larger ones, also contained F-actin (Figures
5B, 5C, 5E, and 5F). Interestingly, the majority of the cells
transfected with the p.Met251Thr mutant contained few
large aggregates, whereas the aggregates in cells transfected
with the p.Ala193Thr mutant were numerous and small
(Table 2).
Discussion
We previously described a large family from Victoria in
Australia with a distal myopathy phenotype, which did
not link to any of the known distal myopathy loci.14 Therican Journal of Human Genetics 88, 729–740, June 10, 2011 735
AB
C
E
F
D
FLNC -EGFP F-acn merge
Figure 5. Transient Transfection of Full-Length Wild-Type
or Mutant Filamin C in PtK2 and C2C12 Cells
Shown are immunoflouorescence micrographs of PtK2 (A, B, and
C) or C2C12 (D, E, and F) cells transfected with full-length,
EGFP-tagged, wild-type (A and D) mutant p.Ala193Thr (B and E)
or mutant p.Met251Thr (C and F) filamin C. Note that in both
cell types all EGFP fusion proteins are targeted to stress fibers.
Only the mutant constructs are additionally localized either in
numerous differentially sized aggregates (B, C, and E) or in one
or a few large aggregates. (F) Note that primarily the larger aggre-
gates (arrowheads) are costained by F-actin. The scale bar repre-
sents 20 mm.
736 The American Journal of Human Genetics 88, 729–740, June 10,distal myopathy in this family is characteristic and distin-
guishable clinically from other distal myopathies by the
first symptom of thenar muscle weakness and later by
posterior calf muscle involvement. On the muscle biopsy,
there was an absence of rimmed vacuoles or markedmyofi-
brillar myopathy changes. The characterization of the clin-
ical phenotype in the Victorian family allowed the identi-
fication of a second Italian family with a similar distal
myopathy. Genome-wide linkage analysis of the Victorian
family identified one significant linkage region on chro-
mosome 7. FLNC was considered the most likely candidate
gene in the linkage region. Analysis of cDNA from affected
family members identified a c.752T>C (p.Met251Thr)
FLNC mutation that is located in the N-terminal ABD of
the protein product. The p.Met251Thr variant segregated
with the disease in the family but was not seen in 400
control chromosomes. A c.577G>A (p.Ala193Thr) muta-
tion was subsequently identified within the filamin C
ABD in the Italian family.
The Filamin Protein Family
FilaminC is amember of the three-member filamin protein
family. Filamin C expression is mainly restricted to skeletal
muscle and the heart in the adult. The other two filamins,
filamin A and filamin B, are ubiquitously expressed.29 The
three filamins share the same basic structure of an
N-terminal ABD and consist of two calponin homology
(CH) domains, followed by 24 Ig-like repeats30 that include
two hinge regions at the 15th and 23rd repeats and a C-
terminal dimerization domain (repeat 24).31 The filamins
are actin cross-linking proteins that play a role in stabilizing
bundles of parallel actin filaments or networks.32 The
ability of filamins to efficiently cross-link actin filaments
results from dimerization of two filamin monomers at the
dimerization domain.33 The filamins are involved in
multiple functions, including control of cell structure, cell
signaling, nuclear signaling, and motion.29,34 Filamin C
in skeletal muscle localizes mainly to the Z disk, where it
bindsmyopodin,35myotilin,16 andFATZ.36A small fraction
of the protein is localized to the sarcolemma,where it binds
sarcoglycans37 and to the myotendinous junction.16 Fila-
min C also plays a role in myogenesis38 and is a substrate
of the muscle-specific calpain 3.39
Known Filamin C Mutations
A mutation in the ABD of filamin C has not previously
been identified. Three disease-causing mutations have
previously been described in filamin C, all associated
with a typical myofibrillar myopathy phenotype [MIM
609524].25,26,40 The first reported FLNC disease-causing
variant was a p.Trp2710X nonsense mutation occurring
within the dimerization domain at the C-terminal end of
the protein25 that alters the dimerization properties of the
protein. Curiously, the other two known mutations are
both in the seventh Ig-like repeat of filamin C, a
12-nucleotide deletion (c.2997_3008del) that removes
four amino acids (p.Val930_Thr933del)26 and a complex2011
Table 2. Analysis of Protein Distribution and Aggregation of Full-Length Wild-Type and Mutant Filamin C-EGFP Fusion Proteins in
Transfected C2C12 Cells
No Aggregates, Fusion
Proteins Associated with
Stress Fibers
Aggregates, Fusion
Proteins Associated
With Stress Fibers 1–3 Large Aggregates > 3 Small Aggregates
Wild-type 100% – – –
p.Met251Thr – 100% 73% 27%
p.Ala193Thr 1% 99% 3% 96%deletion-insertionmutation (c.2695_2712delinsGTTTGTT)
that removes six amino acids and inserts two amino acids
in frame (p.[Lys899_Val904 del]þ[Val899_Cys900ins]).40
The functional consequences of the latter two mutations
await further studies. These three previously reported
mutations are associated with a different pattern of muscle
involvement on MRIs and more proximal weakness25,26,40
than was observed in the two families described in
this paper. Although one myofibrillar myopathy patient
had reported distal weakness of one calf muscle,25 this
condition is still classified as a proximal muscle disease,
whereas the condition described here is a distal myopathy
phenotype.
The muscle pathology associated with the previously
described filamin Cmutations is, similar to all other myofi-
brillar myopathies, characterized by a marked Z disk disin-
tegration and accumulation of myofibrillar proteins.41,42
The presence of nemaline bodies, as seen in the previously
described patients, is a characteristic feature of filamin
myofibrillar myopathy.25,26 Neither florid accumulation
of myofibrillar proteins nor Z disk disintegration character-
istic of the myofibrillar myopathies was seen in any of the
muscle biopsies from the two families presented here.
Thus, muscle pathology findings also support a different
disease mechanism caused by mutations in the ABD of fil-
amin C. Table S4 presents a comparison of the phenotypes
and the pathological features of the two conditions.
Other Filamin and Related Protein Diseases
The ABD of all filamins consists of two calponin homology
domains (CH1 and CH2). Each CH domain contains four
major helices (A, C, E, and G), other minor helical
segments, and nonhelical linkers.28,43,44 This double-CH
domain ABD form is shared by a number of other actin-
binding proteins, including a-actinin, dystrophin, and
utrophin.28,44
The two mutations identified in the distal myopathy
families in the present study, p.Ala193Thr and
p.Met251Thr, are both located in the CH2 domain of the
ABD. A protein sequence alignment of the CH2 domain
in filamin C, filamin A, and filamin B and the orthologous
proteins in green pufferfish, chicken, andDrosophila shows
a 100% conservation of both the p.Ala193 and p.Met251
residues (Figure 3). The two residues are thus highly
conserved throughout evolution and provide further
weight to the conclusion that these are the disease-causing
mutations in the two families.The AmeAlthough mutations have not previously been reported
in the ABD of filamin C, mutations have been described
in the ABD of filamins A and B. Mutations in the ABD of
filamin A result in otopalatodigital syndrome types 1
(OPD1 [MIM 311300]) and 2 (OPD2 [MIM 304120]), fron-
tometaphyseal dysplasia (FMD [MIM 305620]), and Mel-
nick-Needles syndrome (MNS [MIM 309350]).45 Mutations
in the ABD of filamin B result in autosomal-dominant
Larsen syndrome (LRS1 [MIM 150250]), atelosteogenesis
types I (AOI [MIM 108720]) and III (AOIII [MIM
108721]), and boomerang dysplasia (MIM 112310).46 The
homolog of the filamin C p.A193 residue mutated in the
Italian distal myopathy family is mutated in filamin A in
OPD2 (p.Ala200Ser)45 and in filamin B in AOI
(p.Ala173Val).47 A mutation (p.Tyr231Asn) in dystrophin
within the CH2 domain results in Becker muscular
dystrophy [MIM 300376],48 and mutations in the CH2
domain of a-actinin 4 (ACTN4 [MIM 604638]) cause focal
segmental glomerulosclerosis (FSGS1 [MIM 603278]).49
Pathomechanisms of Filamin Mutations
It is well known that mutations in different domains of fil-
amin A and filamin B cause different diseases.45,47 Our
results suggest similar effects for mutations in different
parts of filamin C, because the ABD mutations we have
identified in the Victorian and Italian families result in
a different clinical and pathological phenotype to the
myofibrillar myopathy phenotypes caused by mutations
elsewhere in the gene.
The p.Trp2710X dimerization domain mutation de-
stroys the ability of the protein to dimerize and cross-link
actin, leading to the formation of aggregates of filamin
and its binding partners, desmin, myotilin, and sarcogly-
cans.22 The Ig-like repeat mutations are also associated
with accumulation of filamin and the other proteins that
normally accumulate in myofibrillar myopathies; how-
ever, the exact mechanisms are uncertain.26,40
Our actin-binding studies demonstrate increased actin-
binding affinity of the two distal ABD-filaminopathy
mutations in filamin C. This is similar to previous results
for disease-causing mutations in the actin-binding
domains of filamins A43 and B28 and also for mutations
in the ABD of a-actinin-4 that cause focal segmental glo-
merulosclerosis.49
The following mechanism might explain differences in
binding of wild-type and mutant ABDs to F-actin: the
N-terminal or CH1 domain by itself is able to bind actinrican Journal of Human Genetics 88, 729–740, June 10, 2011 737
filaments, whereas the CH2 domain alone cannot, but
F-actin binding is increased 10-fold when both domains
are present.50,51 Thus, although the CH2 domain does not
possess specific F-actin-binding activity, it contributes to
the binding affinity of the ABD as a whole. The current
model of a-actinin ABD binding to actin filaments suggests
that the presence of CH2 provides steric hindrance to the
binding of F-actin and acts as a negative regulator of the
interaction. Opening of the CH1-CH2 interface is therefore
required for binding.52 The C-terminal helix of the CH2
domain is involved in a number of predominantly hydro-
phobic interactions with the CH1 domain, stabilizing in
this way the closed conformation of the ABD. The amino
acid Met251 resides in this C-terminal helix and plays an
important role in stabilizing the interdomain interaction
interface. The p.Met251Thr mutation changes the hydro-
phobic methionine into a hydrophilic threonine and
results in decreased interdomain interaction and overall
stability of the ABD, as shown by the thermal stability
assays. Although thismutationdoes not alter the secondary
structure significantly, it does increase the binding affinity
to F-actin because of destabilization of the CH1-CH2 inter-
action that facilitates the opening of the ABD required to re-
move the steric clashoccurringwithF-actinoccurring in the
closed conformation. In contrast, the p.Ala193Thr mutant
directly affects the CH2 subdomain, in proximity to the
actin-binding helix C0, and causes a slight alteration of its
binding properties. These observations are consistent with
filamin B mutations within the actin-binding domain that
demonstrate an increased level of actin-binding activity
despite minimal structural changes to the protein.28
In our transient transfection experiments with the
N-terminal constructs, the most obvious difference
between wild-type and mutant ABD domains expressed
on their own was in the nuclear targeting. This was
seen for the p.Met251Thr filamin C mutant and the fila-
min A (p.Glu254Lys) and filamin B (p.Glu227Lys and
p.Ser235Pro) mutants but not for the p.Ala193Thr filamin
C mutation. Filamin A C-terminal fragments are known to
enter the nucleus and play a role in transcription regula-
tion, including androgen receptor transport into the
nucleus.53–56 The role of filamin C in signal transduction,
myogenesis, and muscle regeneration38,57 suggests a role
for it in the nucleus. The results of our overexpression of
the ABDs might support a role for filamin C in the nucleus,
but the physiological relevance of the finding is uncertain.
In addition, the fact that the effect on nuclear localization
was not seen for the p.Ala193Thr filamin C mutation
suggests that the reduced nuclear localization of the
mutant is not primarily responsible for the disease, and
the disease is most likely caused in some way by the
increased affinity for actin.
Transient expression of full-length mutant ABD-filamins
results in aggregation of the expressed proteins together
with F-actin, an effect that is not observed upon transfec-
tion of the wild-type protein, confirming that the aggrega-
tion is caused by the mutations. In corroboration with the738 The American Journal of Human Genetics 88, 729–740, June 10,in vitro actin-binding data, both mutant proteins and
wild-type filamin C all associate with stress fibers. The
increased affinity of the mutants for F-actin is obviously
sufficient for the aggregation of the mutant proteins
together with F-actin. However, in the muscle biopsies of
the patients carrying this mutation, no protein aggregates
were found, which clearly differentiates this disease from
the filamin myopathies described thus far. Possibly the
higher expression levels of the mutant protein in trans-
fected cells compared to the expression levels in muscle
fibers or the absence of wild-type filamin C in the trans-
fected cells is the reason for this discrepancy.Conclusions
The finding that mutations within the ABD of FLNC result
in the distal myopathy in two different families we
describe adds understanding to filamin C biology and
suggests a different patient cohort should be screened for
FLNC mutations. All known FLNC mutations cause adult-
onset muscle disease. Whereas a partial ablation of both
FLNC alleles results in severe defects in myogenesis and
neonatal lethality in mice,38 the heterozygous FLNCmuta-
tions found thus far in patients do not seem to greatly
affect muscle biology. Our data most strongly support
that the disease mechanism, similar to the disease mecha-
nism for ABD mutations in filamins A and B, involves
increased affinity for actin. Further work is required to fully
understand the pathobiology of distal ABD-filaminopathy.Supplemental Data
Supplemental Data include six figures and four tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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